For this comparison, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last October I sat in on a telehealth consult where a 46-year-old woman in Tampa, a middle school teacher named Rachel, asked her prescriber the exact question I hear in some version every week: “Which one should I be on?” She’d been on semaglutide 1.7 mg for five months, lost about 9% of her body weight, hit a wall, and her coworker was raving about tirzepatide. Her prescriber pulled up her labs, paused, and said something I thought was perfect: “The better drug is the one that works for your body at a dose you can tolerate and a price you can sustain.” That’s not a dodge. It’s the honest answer. But it deserves unpacking.
The Numbers Everyone Quotes (and What They Actually Tell You)
Tirzepatide wins the headline contest. SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks in adults with obesity. STEP-1 (Wilding et al., NEJM 2021) reported 14.9% mean weight loss with semaglutide 2.4 mg over 68 weeks. Head-to-head data from SURMOUNT-5 confirmed the gap directly: tirzepatide produced greater mean weight loss than semaglutide over 72 weeks.
So tirzepatide is the obvious choice, right? Not so fast.
Those are means. Within the STEP-1 data, individual responders ranged widely. Some people on semaglutide lost 20%+. Some people on tirzepatide 15 mg lost less than 10%. Trial populations are selected, adherent, and monitored in ways that don’t perfectly map onto your life with a demanding job, a family, and a pharmacy that may or may not have stock this month.
The boring truth: population averages are useful for comparing molecules. They’re mediocre for predicting what happens to you specifically.
Why Two Receptors Might Be Better Than One
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. Think of it like this: semaglutide is a single-lane highway into appetite suppression and glucose regulation, while tirzepatide runs two lanes. More traffic gets through.
Whether that GIP receptor activity explains the weight loss gap is still being studied, but the head-to-head data suggests it matters. The shared GLP-1 activity is also why the side effect profiles overlap so heavily. Nausea, diarrhea, constipation: those are GLP-1 receptor problems, and switching molecules doesn’t always fix them.
Some patients do tolerate one better than the other for reasons that are poorly understood at the individual level. Rachel, the teacher in Tampa, ended up switching to tirzepatide and found her nausea actually decreased, even though the trial data wouldn’t have predicted that. Biology is personal.
Titration: The Part People Rush
Standard tirzepatide dosing starts at 2.5 mg weekly for four weeks. This is not a therapeutic dose for most people. It’s a GI tolerance phase. Most patients lose minimal weight here, and the ones who get discouraged at week three are making a decision too early.
The real action begins at 5 mg (weeks 5 through 8), where meaningful appetite reduction typically kicks in. From there, escalation proceeds at four-week intervals: 7.5, 10, 12.5, and up to the maximum labeled dose of 15 mg.
| Phase | Typical dose | Duration | Notes | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1 to 4 | GI tolerance, not weight loss | | Step 1 | 5 mg weekly | Weeks 5 to 8 | First meaningful appetite reduction | | Step 2 | 7.5 mg weekly | Weeks 9 to 12 | Some patients hold here if response is adequate | | Step 3 | 10 mg weekly | Weeks 13 to 16 | Common long-term maintenance tier | | Step 4 | 12.5 mg weekly | Weeks 17 to 20 | For patients with attenuating response | | Step 5 | 15 mg weekly | Week 21 onward | Maximum labeled dose; not everyone needs this |
Not every patient needs to reach 15 mg. Many stabilize somewhere between 5 and 10 mg once they hit their goal weight, balancing continued benefit against side effects and cost.
One practical note: compounded preparations sometimes allow intermediate doses like 6.25 or 8.75 mg that aren’t available in branded autoinjectors. For patients who are borderline tolerating a dose increase, that granularity is genuinely helpful.
Branded vs. Compounded: What You’re Actually Comparing
The active ingredient in a compounded tirzepatide preparation is tirzepatide. Same molecule. The differences sit at the level of manufacturing oversight, regulatory pathway, packaging, and price.
Branded Zepbound and Mounjaro are FDA-approved finished drugs manufactured by Eli Lilly under cGMP standards, with established labeling and post-marketing surveillance infrastructure. Compounded preparations come from 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (cGMP-inspected, may produce office stock).
Here’s the catch: compounded preparations are not FDA-evaluated for safety, efficacy, or quality the way branded products are. The regulatory framework depends on state pharmacy board oversight, federal 503A/503B requirements, and individual prescriber judgment. That’s a meaningful difference, and patients considering compounded options should ask about pharmacy state licensure, whether the pharmacy holds any accreditation, what clinical oversight looks like (an actual clinician evaluation, not just a form submission), and whether pricing is transparent.
Patients exploring this choice in more depth often find this comparison a useful reference. It expands on dosing specifics, monitoring protocols, and the regulatory context shaping patient decisions in 2026.
Side Effects: What to Expect and When to Worry
GI symptoms dominate. Nausea hits 30 to 45% of patients in trial populations. Diarrhea, constipation, and vomiting follow. Most of this concentrates in the first 4 to 8 weeks and around dose escalations, peaking shortly after a step-up and then fading over 2 to 3 weeks at a stable dose.
| Symptom | Reported frequency | Typical timing | Management | |—|—|—|—| | Nausea | 30 to 45% | First 4 to 8 weeks, worse with dose increases | Smaller meals, lower fat, water sipping, antiemetic if persistent | | Diarrhea | 15 to 23% | Variable | Hydration, electrolyte review, BRAT-style meals briefly | | Constipation | 10 to 17% | Often after GI motility slows | Fiber 25 to 35 g daily, hydration, magnesium if cleared by clinician | | Vomiting | 8 to 13% | First weeks and escalations | Hold dose, consult prescriber if persistent | | Reflux | 7 to 12% (often underreported) | Throughout therapy | Avoid eating within 3 hours of bedtime, raise head of bed | | Fatigue | Variable | First weeks | Usually self-resolves; check ferritin, B12, thyroid if persistent |
The serious stuff: pancreatitis, gallbladder disease, severe hypoglycemia (especially combined with insulin or sulfonylureas), kidney injury from dehydration, and a boxed warning for medullary thyroid carcinoma based on rodent studies. Severe abdominal pain radiating to the back warrants immediate clinician contact.
Baseline labs worth getting before you start: comprehensive metabolic panel, HbA1c and fasting glucose, lipid panel, TSH, lipase (especially with any personal history of pancreatitis), and CBC. Recheck at 12 to 16 weeks, then roughly every 6 months once stable.
Switching Between the Two
This comes up constantly. A few common scenarios:
Semaglutide to tirzepatide (plateau): Begin tirzepatide at 2.5 mg the week after your last semaglutide dose. Do not try to dose-match. You start over on the titration ladder.
Tirzepatide to semaglutide (cost or insurance): Begin semaglutide at 0.25 mg. Expect a re-acclimation period similar to starting fresh.
Switching for side effect intolerance: This is where I think people get it wrong most often. If the side effect is GLP-1 receptor-mediated (and most GI symptoms are), switching molecules may not help at all. Address the side effect first: slow the titration, adjust the diet, hold at a lower dose. Only if that fails does a switch make clinical sense.
Do not switch on your own. The transition involves dose pacing, monitoring, and managing the gap between medications. And switching is contraindicated during pregnancy planning or in patients with absolute contraindications to both molecules.
Frequently Asked Questions
Which produces more weight loss?
Head-to-head data from SURMOUNT-5 reported greater mean weight loss with tirzepatide than semaglutide over 72 weeks. SURMOUNT-1 reported up to 20.9% mean loss at 15 mg tirzepatide. STEP-1 reported up to 14.9% with semaglutide 2.4 mg.
Which is better tolerated?
GI side effect profiles are broadly similar because both activate the GLP-1 receptor. Individual tolerance varies, and switching is sometimes used clinically when one is poorly tolerated.
How do the dosing schedules differ?
Tirzepatide: 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. Semaglutide for weight management (Wegovy): 0.25, 0.5, 1.0, 1.7, and 2.4 mg weekly. The numbers aren’t comparable across products because the molecules are different.
Which is cheaper?
Compounded versions of either typically cost less than branded. Branded Zepbound and Wegovy retail prices are in similar ranges, though manufacturer self-pay programs vary.
Can I take both at the same time?
Combining GLP-1 agonists is not standard clinical practice and is not supported by trial data.
Which works faster?
Onset of appetite suppression is similar: typically within the first 2 to 4 weeks. Weight loss accelerates as the dose increases.
Should I choose based on trial data alone?
No. Trial data tells you about population averages. Your decision should also factor in your medical history, tolerance, cost, insurance coverage, and prescriber recommendation.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
